FA
MRK icon

Fagan Associates’s Merck MRK Stock Holding History

Fagan Associates’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267K Hold
2,075
– – 0.03% 122
2026
Q1 		$250K Sell
2,075
-43
-2% -$4.96K 0.03% 122
2025
Q4 		$223K Buy
+2,118
New +$199K 0.03% 127
2025
Q2 		– Sell
-2,597
Closed -$233K – 133
2025
Q1 		$233K Buy
2,597
+200
+8% +$18.7K 0.04% 115
2024
Q4 		$238K Hold
2,397
– – 0.04% 123
2024
Q3 		$272K Sell
2,397
-98
-4% -$11.6K 0.05% 117
2024
Q2 		$309K Hold
2,495
– – 0.05% 105
2024
Q1 		$329K Buy
2,495
+100
+4% +$12.3K 0.06% 105
2023
Q4 		$261K Sell
2,395
-100
-4% -$10.4K 0.06% 103
2023
Q3 		$257K Buy
2,495
+75
+3% +$8.08K 0.06% 103
2023
Q2 		$279K Buy
2,420
+68
+3% +$7.72K 0.07% 100
2023
Q1 		$250K Hold
2,352
– – 0.06% 112
2022
Q4 		$261K Hold
2,352
– – 0.07% 109
2022
Q3 		$203K Hold
2,352
– – 0.06% 116
2022
Q2 		$214K Buy
+2,352
New +$209K 0.06% 115

Other funds holding MRK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fagan Associates's MRK Position: Q2 2026 in Review

Fagan Associates held its Merck (MRK) position steady in Q2 2026 at 2,075 shares worth $267K. The position accounts for 0.03% of the portfolio, ranked #122.

Fagan Associates first reported a position in MRK in Q2 2022 and has held it in 15 quarters since. The position peaked at $329K in Q1 2024. 3,852 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Fagan Associates held 2,075 shares of Merck worth $267K as of Q2 2026.
  • Fagan Associates left its Merck share count unchanged in Q2 2026.
  • Merck made up 0.03% of Fagan Associates's portfolio in Q2 2026, its #122 holding.
  • Fagan Associates first reported a position in Merck in Q2 2022 and has held it in 15 quarters since.
  • Fagan Associates's Merck position peaked at $329K in Q1 2024.
  • 3,852 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Fagan Associates's 13F filing for Q2 2026, filed 4 Aug 2026.